“生物安全法案”大局敲定：CXO行业估值反弹在即，创新药国际化迎新转机

七印授权

5L4ETYMJWZQ6INFFPV8RXBP5YZUO5G5ZRI4KF4PQMSBH6CBEQ8

2024-12-09 07:42:11

article

2799492A6AEF00F4E8304CE89FB96DDAB06C6EBC5FDB96CA837AAB3168529241

zh-CN

6AA65AC6E96ABA00CD06D93C909C0BCCE448138B

17554563

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

ec2709319b08712c19b05553fa548152050d5b19449ff90caa8f111ba66175543f19e34f03bd062b7ccd68368df33b6c85d21ed1d928551e66e8bb19ac6e46c21b

{"parameters":{"adaptation":"n","authorized":"七印信息科技","price":"180000"},"type":"cm"}

yuanben_67569f530d55f3.94456514

原本认证

645WBZHO382A0BXLU81HO8ZNUODBTWBSEXXC4170ILTDN0DS6S

https://www.yuanben.io/article/639396d0-ca3b-4cfa-8f7b-00a6e5849ba2

{"author":"广东南方财经控股有限公司","authorization_pub_key":"03db333a8335fc94ab2e27ec5b937827ece2e576ae219f93ea1083a9a4f8882dc2"}